Medical/Pharmaceuticals APAC News & Press Release Distribution

BIAL Award in Biomedicine worth 300,000 Euros, nominations until 30 June

PORTO, Portugal, June 7, 2021 /PRNewswire/ -- The second edition of the BIAL Award in Biomedicine is currently underway. Worth three hundred thousand Euros, this prize is intended to reward a work with exceptional quality results and scientific relevance published in the last ten years in the bro...

2021-06-07 10:00 1457

OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting

SHANGHAI, June 7, 2021 /PRNewswire/ -- On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) Co., Ltd. ("OriginCell"), together with Lishui Central Hospital affiliated toZhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001,...

2021-06-07 10:00 3560

OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting

Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021

* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in the safety analysis. ORR was 55.6%, and DCR was 88.9%. * The updated results from this Phase II study will be presented at an upcoming medical meeting. A phase III clinical study of KN046 in combinat...

2021-06-07 09:53 5793

Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for ch...

2021-06-07 08:30 3039

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7660

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7898

Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7613

Arctic Vision Announces Exclusive Licensing Agreement with Olympic Ophthalmics for iTEAR®100 for the Treatment of Dry Eye Disease in Greater China, South Korea and ASEAN countries

ISSAQUAH, Wash. and SHANGHAI, June 7, 2021 /PRNewswire/ -- Arctic Vision, a clinical stage biotech company focusing on innovative ophthalmology therapies for pan-ocular diseases, and Olympic Ophthalmics, a U.S.-based medical technology company pioneering neuromodulation treatments for ophthalmic ...

2021-06-07 08:00 2156

Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7515

Samsung Pharm & GemVax present pancreatic cancer immunotherapeutic drug, RIAVAX™, phase III results at ASCO 2021

SEOUL, South Korea, June 5, 2021 /PRNewswire/ -- Samsung Pharm Co., Ltd. announced today that the company presented the results of a phase III clinical trial of its pancreatic cancer immunotherapeutic drug candidate called 'RIAVAX™ (GV1001)' conducted in Korea at the 2021 American Society of Clin...

2021-06-05 20:00 3191

Advaccine Announces First Participants Dosed in Phase 2 Study of ADV110 Evaluating Respiratory Syncytial Virus (RSV) Vaccine Candidate in Australia

SUZHOU, China, June 4, 2021 /PRNewswire/ -- Advaccine Biopharmaceuticals ("Advaccine") announces that the first participants have been successfully dosed in its phase 2 study of ADV110, a respiratory syncytial virus (RSV) prophylactic vaccine candidate, inAustralia. The phase 2 study is a two-ce...

2021-06-04 20:05 3541

Oxygen Concentrators have arrived, 135 oxygen concentrators donated by Fosun and its friendly enterprises arrive in Mumbai

HONG KONG, June 4, 2021 /PRNewswire/ -- On 1 June 2021, 135 oxygen concentrators, 5 ventilators, and 3,300 KN95 masks donated by Fosun Foundation ( Shanghai) (hereinafter referred to as "Fosun Foundation") and its friendly enterprises arrived inMumbai. This is the largest batch of oxygen concentra...

2021-06-04 16:48 2289

Sihuan Pharmaceutical (0460.HK) Obtained the Exclusive Distribution Right for LipiVage(R) Fat Collection System in Greater China and South Korea

HONG KONG, June 4, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that Meiyen Laboratory Inc, an Am...

2021-06-04 14:03 9226

DiNovA's Israel Incubator officially opens its office in Caesarea

CAESAREA, Israel, June 4, 2021 /PRNewswire/ -- China headquartered DiNovA Medtech officially takes up residence in Caesarea Industry and Business Park for itsIsrael incubator, which continues to help augment the company's global footprint. DiNovA Medtech is not new to Israel. Its leadership team...

2021-06-04 14:00 1863

Elekta Nomination Committee's proposed Board of Directors for the 2021 Annual General Meeting

STOCKHOLM, June 4, 2021 /PRNewswire/ -- The Nomination Committee of Elekta (EKTA-B.ST) proposes that the 2021 Annual General Meeting re-elect Board members Laurent Leksell, who is also proposed to be re-elected as Chairman of the Board, Caroline Leksell Cooke, Johan Malmquist, Wolfgang Reim, Jan Se...

2021-06-04 13:56 2047

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

SHANGHAI and HONG KONG, June 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...

2021-06-04 08:00 3109

Vela Diagnostics Announces Collaboration with the National Cancer Centre of Singapore to Refine Novel Cancer Therapy

SINGAPORE, June 4, 2021 /PRNewswire/ -- Vela Diagnostics announced a collaboration with the National Cancer Centre ofSingapore (NCCS) to develop a molecular diagnostic assay to predict individual patients' responses to a cancer therapy called Epidermal Growth Factor Receptor (EGFR) tyrosine kinas...

2021-06-04 08:00 2017

WCPGHAN 2021: Fish oil taken during pregnancy boosts problem-solving and concentration in children, new data reveals

GENEVA, June 4, 2021 /PRNewswire/ -- Children born to mothers who took fish oil in their pregnancies have been shown to have faster problem-solving skills and better attention focus at age 10, according to findings from an EU funded study presented today at the 6th World Congress of Paediatric Ga...

2021-06-04 07:01 2410

The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial

1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathy...

2021-06-04 02:00 2151

Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...

2021-06-03 17:09 4758